DEXAMETHASONE

Efficacy

Shandong Provincial HospitalSmall moleculePhase 4 / ApprovedDormant

BB

64/ 100

Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence: 53/ 100
Competitive Position: 81/ 100

Competitive context

24 Active assets in the Efficacy cohort.

Asset / Sponsor	Phase	Rating
Metformin Xijing Hospital	Phase 4	BB
Pioglitazone Xijing Hospital	Phase 4	B
Sodium Oligomannate First Affiliated Hospital Xi'an Jiaotong University	Phase 4	B
gv-971 First Affiliated Hospital Xi'an Jiaotong University	Phase 4	B
Irinotecan Assiut University	Phase 3	B

View all 37 →

Same molecule, other indications

DEXAMETHASONE is also rated in:

chemotherapy-induced toxicityDormant

A

Indicative ·

82 / 100

adult acute lymphoblastic leukemiaDormant

BBB

Indicative ·

79 / 100

B-cell childhood acute lymphoblastic leukemiaDormant

BBB

Indicative ·

78 / 100

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.